Some Winners Emerge Despite China’s Reimbursement Price-Cutting Scheme
Higher Volumes Benefit Selected PD-1s
Inclusion into China's national reimbursement drug list alone does not guarantee revenue growth but in some cases higher volumes seem to be offsetting the requisite big price cuts, reveal second-quarter results from some leading publicly-traded biotechs in the country.
